Targeted Therapy vs Immunotherapy: — Which One Is Right for You?

Neither is better overall — the right one is the one matched to your tumour's biology. Targeted therapy can produce deep responses in patients whose cancers carry the right mutation. Immunotherapy can produce durable responses in patients whose tumours express the right markers. Each is designed for a different biological situation, and neither is useful where its specific conditions are absent. What matters is which one fits your individual tumour, and that is a question your biopsy results answer.

Sometimes, yes — certain treatment protocols combine both, but this is a specific clinical decision, not something you can request as an upgrade. Combination regimens are approved in some cancer types and studied in others. They also carry the side effects of both treatments, which affects who is fit enough to receive them. Your oncologist will tell you whether a combined approach is appropriate for your cancer type and your current health.

Biomarker testing on your tumour tissue determines eligibility for both. For targeted therapy, the laboratory looks for specific gene mutations or alterations — such as EGFR, ALK, BRAF, HER2, or others depending on your cancer type. For immunotherapy, the key markers include PD-L1 expression, microsatellite instability, and tumour mutational burden. Which tests matter depends on where your cancer started. Most can be run on the biopsy tissue you have already provided; a new biopsy is only needed if the original sample is too small or too old.

Cancer cells can develop new mutations over time that allow them to bypass the pathway the drug was blocking. This is called acquired resistance, and it is a recognised limitation of targeted agents. When it happens, your oncologist may order a repeat biopsy or a liquid biopsy to identify the new change, then consider a second-generation drug or a different treatment altogether. Regular monitoring during treatment is partly designed to catch this early, rather than waiting for clear symptoms of progression.

Yes, substantially. Targeted therapy causes fewer of the classic chemotherapy side effects — severe nausea and widespread hair loss are less common — but it carries its own effects, including rash, diarrhoea, fatigue, and changes to nails or skin, depending on the specific drug. Immunotherapy side effects are different again: they arise from immune activation and can affect the gut, liver, lungs, skin, or hormone glands. Both can cause serious reactions that need prompt medical attention, and your team will tell you which symptoms to report the same day.

Targeted therapy is typically continued for as long as it is working and you can tolerate it — there is no fixed number of cycles the way chemotherapy often has. Treatment is stopped if the cancer stops responding, if side effects become unmanageable, or sometimes when a prolonged complete response has been achieved. Duration varies from months to years depending on the drug, the cancer type, and how the disease behaves. Your oncologist will discuss what monitoring is planned and what the stopping criteria are for your specific regimen.

Being ineligible for both targeted therapy and immunotherapy does not mean you are out of options. Chemotherapy, hormone therapy, radiation, surgery, or combinations of these remain effective for many cancers. Eligibility can also change — tumours evolve, and new evidence emerges steadily for different cancer types. If your disease behaves differently later, the question may be worth revisiting. Ask your oncologist to explain clearly which treatment is recommended and what it is expected to achieve, so you have a complete picture of the plan.

Yes. Both targeted therapy and immunotherapy are administered at CION centres across Telangana and Andhra Pradesh, and both are given as day care — most patients do not need an overnight stay. Biomarker testing to determine eligibility is coordinated as part of your treatment workup. Response assessment scans such as PET-CT are done through partner imaging centres. CION does not offer CAR-T or cell therapy; if that becomes relevant to your treatment, your team will refer you to a centre that provides it.